Jonathan Michael Campbell, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 1650 Cochrane Cir # B7500, Ft Carson, CO 80913 Phone: 719-526-2092 Fax: 719-526-7732 |
Patrick Beebe, DO General Practice Medicare: Not Enrolled in Medicare Practice Location: 1650 Cochrane Cir B7500, Ft Carson, CO 80913 Phone: 719-526-7000 |
Dr. Christopher Merle Nystuen, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 1650 Cochrane Cir, Department Of Medical Readiness, Ft Carson, CO 80913 Phone: 719-524-7351 |
Katherine Buechner, General Practice Medicare: Not Enrolled in Medicare Practice Location: 1650 Cochrane Cir # B7500, Ft Carson, CO 80913 Phone: 719-526-7000 |
News Archive
In 2009 a student research project investigating a low frequency therapy for temporary tinnitus was joint runner-up in the 2009 BT Young Scientist and Technology Exhibition, held in Dublin, Ireland. The student research project which has now evolved into a web-based company, Restored Hearing (www.restoredhearing.ie) was one of the companies which showcased recently at the 2010 exhibition.
Genzyme Corporation today announced that it has completed the sale of its diagnostic products business to Sekisui Chemical Co., Ltd. for $265 million in cash.
BioMedical Enterprises announced the launch of the Speed Titan Nitinol Bone Fixation Implant today. As the newest addition to the BME Speed Fixation System, the Speed Titan joins the BME Speed, Speed Arc and Speed Shift™ implants to create the world's most comprehensive family of continuous active compression Nitinol implants.
Emerson Resources, Inc., a premier pharmaceutical solutions company, today announced that it has formed a strategic partnership with Bio Research, a contract research organization that specializes in the agrichemical and related industries, to further extend its business development capabilities. The exclusive partnership leverages the expertise of industry veteran Robert Westbrook, CEO of Bio Research, who is spearheading Emerson Resources' intensified business development and sales efforts.
GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine], the first combination vaccine to offer protection against diphtheria, tetanus, pertussis and polio diseases in one shot.
› Verified 2 days ago